INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.
A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus.
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Antigens produced by various strains of HEPATITIS D VIRUS.
The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
INFLAMMATION of the LIVER in humans caused by a member of the HEPATOVIRUS genus, HUMAN HEPATITIS A VIRUS. It can be transmitted through fecal contamination of food or water.
Any of the viruses that cause inflammation of the liver. They include both DNA and RNA viruses as well viruses from humans and animals.
Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.
INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).
Antigens from any of the hepatitis viruses including surface, core, and other associated antigens.
The hepatitis B antigen within the core of the Dane particle, the infectious hepatitis virion.
Antigens of the virion of the HEPATITIS B VIRUS or the Dane particle, its surface (HEPATITIS B SURFACE ANTIGENS), core (HEPATITIS B CORE ANTIGENS), and other associated antigens, including the HEPATITIS B E ANTIGENS.
INFLAMMATION of the LIVER.
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A frequent complication of drug therapy for microbial infection. It may result from opportunistic colonization following immunosuppression by the primary pathogen and can be influenced by the time interval between infections, microbial physiology, or host resistance. Experimental challenge and in vitro models are sometimes used in virulence and infectivity studies.
Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.
INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.
Ribonucleic acid that makes up the genetic material of viruses.
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
A positive-stranded RNA virus species in the genus HEPEVIRUS, causing enterically-transmitted non-A, non-B hepatitis (HEPATITIS E).
Antibodies to the HEPATITIS A ANTIGENS including antibodies to envelope, core, and non-structural proteins.
INFLAMMATION of the LIVER in animals due to viral infection.
A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES.
A strain of HEPATITIS A VIRUS which causes hepatitis in humans. The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the fecal-oral route.
INFLAMMATION of the LIVER in non-human animals.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A species of the CORONAVIRUS genus causing hepatitis in mice. Four strains have been identified as MHV 1, MHV 2, MHV 3, and MHV 4 (also known as MHV-JHM, which is neurotropic and causes disseminated encephalomyelitis with demyelination as well as focal liver necrosis).
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Antigens of the virions of HEPACIVIRUS, their surface, core, or other associated antigens.
A genus of PICORNAVIRIDAE causing infectious hepatitis naturally in humans and experimentally in other primates. It is transmitted through fecal contamination of food or water. HEPATITIS A VIRUS is the type species.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Antigens produced by various strains of HEPATITIS A VIRUS such as the human hepatitis A virus (HEPATITIS A VIRUS, HUMAN).
INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
A DNA virus that closely resembles human hepatitis B virus. It has been recovered from naturally infected ducks.
An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.
Deoxyribonucleic acid that makes up the genetic material of viruses.
Proteins encoded by a VIRAL GENOME that are produced in the organisms they infect, but not packaged into the VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
An ORTHOHEPADNAVIRUS causing chronic liver disease and hepatocellular carcinoma in woodchucks. It closely resembles the human hepatitis B virus.
Tumors or cancer of the LIVER.

Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. (1/157)

Viral hepatitis constitutes a major health issue, with high prevalence among injecting drug users (IDUs). The present study assessed the prevalence and risk determinants for hepatitis B, C and D viruses (HBV, HCV and HDV) infections among 102 IDUs from Rio de Janeiro, Brazil. Serological markers and HCV-RNA were detected by enzyme immunoassay and nested PCR, respectively. HCV genotyping was determined by restriction fragment length polymorphism analysis (RFLP). HBsAg, anti-HBc and anti-HBs were found in 7.8, 55.8 and 24. 7% of IDUs, respectively. In the final logistic regression, HBV infection was independently associated with male homosexual intercourse within the last 5 years (odds ratio (OR) 3.1; 95% confidence interval (CI) 1.1-8.8). No subject presented anti-delta (anti-HD). Anti-HCV was detected in 69.6% of subjects, and was found to be independently associated with needle sharing in the last 6 months (OR 3.4; 95% CI 1.3-9.2) and with longer duration of iv drug use (OR 3.1; 95% CI 1.1-8.7). These data demonstrate that this population is at high risk for both HBV and HCV infection. Among IDUs from Rio de Janeiro, unprotected sexual intercourse seems to be more closely associated with HBV infection, whereas HCV is positively correlated with high risk injecting behavior. Comprehensive public health interventions targeting this population and their sexual partners must be encouraged.  (+info)

Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. (2/157)

Hepatitis B (HBV) and C viral (HCV) dual-infection-associated liver disease is an uncommon indication for liver transplantation. The clinical and virologic outcomes in such patients have not been well studied. We retrospectively studied 13 patients with hepatitis B surface antigen (HBsAg) and antibody to HCV positivity who underwent orthotopic liver transplantation (OLT) and survived at least 30 days post-OLT. Antibody to hepatitis delta virus (HDV) was negative in 8 patients (group I) and positive in 5 patients (group II). Eleven of the 13 patients received standard hepatitis B immune prophylaxis, and they all remained HBsAg negative. All group I patients were HCV RNA positive after transplantation; in contrast, all group II patients were HCV RNA negative. Serum alanine aminotransferase levels were elevated in 88% (7 of 8) of the patients in group I compared with 20% (1 of 5 patients) in group II. None of the patients had graft loss from chronic rejection or recurrent hepatitis. Three patients had unsuspected hepatocellular carcinoma in the explant. We conclude that among liver transplant recipients with HBV and HCV coinfection, HDV infection is associated with the suppression of HCV replication and mild inflammatory activity after OLT.  (+info)

Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). (3/157)

BACKGROUND: The effect of hepatitis delta virus (HDV) infection on the clinical course of cirrhosis type B is poorly defined. AIMS: To investigate the impact of HDV status on morbidity and mortality in cirrhosis type B. PATIENTS/METHODS: Retrospective cohort study of 200 Western European patients with compensated cirrhosis type B followed for a median period of 6.6 years. RESULTS: At diagnosis, 20% of patients had antibodies to HDV (anti-HDV); median age was lower in anti-HDV positive cirrhotics (34 v 48 years respectively). Kaplan-Meier five year probability of hepatocellular carcinoma (HCC) was 6, 10, and 9% in anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive cirrhotics respectively; the corresponding figures for decompensation were 22, 16, and 19% and for survival they were 92, 89, and 83% respectively. Cox regression analysis identified age, albumin concentration, gamma-globulin concentration, and HDV status as significant independent prognostic variables. After adjustment for clinical and serological differences at baseline, the risk (95% confidence interval) for HCC, decompensation, and mortality was increased by a factor of 3.2 (1.0 to 10), 2.2 (0.8 to 5.7), and 2.0 (0.7 to 5.7) respectively in anti-HDV positive relative to HDV negative cirrhotic patients. The adjusted estimated five year risk for HCC was 13, 4, and 2% for anti-HDV positive/HBeAg negative, anti-HDV negative/HBeAg negative, and anti-HDV negative/HBeAg positive cirrhotics respectively; the corresponding figures for decompensation were 18, 8, and 14% and for survival 90, 95, and 93% respectively. CONCLUSIONS: HDV infection increases the risk for HCC threefold and for mortality twofold in patients with cirrhosis type B.  (+info)

Prevalence of hepatitis B, D and C virus infections among children and pregnant women in Moldova: additional evidence supporting the need for routine hepatitis B vaccination of infants. (4/157)

Rates of acute hepatitis B are high in Moldova, but the prevalence of chronic infection is unknown. In 1994, we surveyed children and pregnant women, collected demographic information, and drew blood for laboratory testing. Among the 439 children (mean age, 5 years), the prevalence of antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were 17.1 and 6.8%, respectively. Among the 1098 pregnant women (mean age, 26 years), 52.4% were anti-HBc-positive and 9.7% were HBsAg-positive. Of the HBsAg-positive pregnant women, 35.6% were hepatitis B e antigen (HBeAg) positive and 18.3% had antibodies to hepatitis D virus. The prevalence of antibody to hepatitis C virus was 1.4% in children and 2.3% in pregnant women. The high HBeAg prevalence among HBsAg-positive pregnant women and the high anti-HBc prevalence among children indicate that both perinatal and early childhood transmission contribute to the high hepatitis B virus endemicity in Moldova.  (+info)

Origin of hepatitis delta virus mRNA. (5/157)

Hepatitis delta virus (HDV) is unique relative to all known animal viruses, especially in terms of its ability to redirect host RNA polymerase(s) to transcribe its 1,679-nucleotide (nt) circular RNA genome. During replication there accumulates not only more molecules of the genome but also its exact complement, the antigenome. In addition, there are relatively smaller amounts of an 800-nt RNA of antigenomic polarity that is polyadenylated and considered to act as mRNA for translation of the single and essential HDV protein, the delta antigen. Characterization of this mRNA could provide insights into the in vivo mechanism of HDV RNA-directed RNA transcription and processing. Previously, we showed that the 5' end of this RNA was located in the majority of species, at nt 1630. The present studies show that (i) at least some of this RNA, as extracted from the liver of an HDV-infected woodchuck, behaved as if it contained a 5'-cap structure; (ii) in the infected liver there were additional polyadenylated antigenomic HDV RNA species with 5' ends located at least 202 nt and even 335 nt beyond the nt 1630 site, (iii) the 5' end at nt 1630 was not detected in transfected cells, following DNA-directed HDV RNA transcription, in the absence of genome replication, and (iv) nevertheless, using in vitro transcription with purified human RNA polymerase II holoenzyme and genomic RNA template, we did not detect initiation of template-dependent RNA synthesis; we observed only low levels of 3'-end addition to the template. These new findings support the interpretation that the 5' end detected at nt 1630 during HDV replication represents a specific site for the initiation of an RNA-directed RNA synthesis, which is then modified by capping.  (+info)

Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. (6/157)

Until 1991, the Russian city of Samara was largely isolated from other parts of Russia and the rest of the world. Very recently, Samara has seen an alarming increase in the incidence of hepatitis. The proportion of fulminant cases is unusually high. We wanted to assess the roles of hepatitis B virus (HBV) and hepatitis D virus (HDV) in acute viral hepatitis in this region by analyzing the prevailing strains of both and by determining their genotypes and possible origin. Serum samples were screened for different serological markers and by PCR followed by direct sequencing. Of the 94 HBV-positive samples (80% of which were acute infections), 37 (39%) were also HDV positive. Sixty-seven percent of the patients had anti-HCV antibodies. Twenty-five percent of all patients in the study had fulminant hepatitis. Statistically significant sex differences were found among fulminant cases. For HBV, the core promoter sequences of 62 strains were determined and all but one were found to be of genotype D. None of these had any deletions. Only one strain, from a patient with fulminant fatal hepatitis, showed multiple mutations. The pre-S2 region sequences of 31 HBV strains were also compared. Phylogenetically, these fell into two distinct groups within genotype D, suggesting different origins. For HDV, part of the region encoding the delta-antigen was sequenced from four strains. All proved to be of genotype I and were similar to Far Eastern and Eastern European strains. The contribution of intravenous drug use to the sharp increase in viral hepatitis in this unique setting is discussed.  (+info)

Efficient site-specific nonribozyme opening of hepatitis delta virus genomic RNA in infected livers. (7/157)

Examination of the 1,679-nucleotide (nt) unit-length hepatitis delta virus (HDV) RNAs in the livers of two HDV-infected woodchucks showed that 96% of the antigenomic RNA but only 50% of the genomic RNA was circular. We subsequently found that at least half of the linear unit-length genomic RNA was open at a unique location. Using a modified form of RNA ligation-mediated amplification of cDNA ends, we showed that the 5' end was located at nt 1212. Like the previously described ribozyme cleavage site at nt 686, the new site produced a 5'-OH. Nevertheless, we showed that this novel site was not produced by activity of the HDV genomic ribozyme. We speculate that the 5' end at nt 1212 reflects a preferred site of posttranscriptional endonucleolytic cleavage of genomic RNA.  (+info)

HBV, HCV and HDV infections in Albanian refugees in Southern Italy (Apulia region). (8/157)

The seroprevalence of hepatitis B, C and D markers was assessed in a sample of 670 Albanian refugees in Southern Italy in 1997. The mean age was 25 years (S.D. = 12.3). Of study subjects 62.1% (95% CI: 58.4-65.7) were positive for anti-HBc antibodies and 13.6% (95% CI: 10.9-16.1) for HBsAg. The prevalence of anti-HBs was 47.6% (95% CI: 43.8-51.3). Among HBsAg carriers the prevalence of HBeAg was 7.7% (95% CI: 2.2-13.1). The highest carrier rate for HBsAg (25.5%; 95% CI: 16.7-34.3) was found in the age group 21-25 years. A relevant finding was a prevalence of HBsAg of 8.1% in children 10 years and under. The prevalence of anti-HCV antibodies was 0.3% (95% CI: 0.0-0.7) while only one of the HBsAg carriers was positive for anti-HDV (1.1%, 95% CI: 0-3.2). In Albania, hepatitis B infection represents a public health priority that should be addressed by a universal vaccination campaign.  (+info)

Hepatitis D, also known as Delta hepatitis, is a viral infection of the liver that can only occur in people who have a current infection with the hepatitis B virus (HBV). It's caused by the hepatitis delta virus (HDV), which is a small, enveloped, single-stranded RNA virus.

HDV requires the presence of HBV for its replication and survival, so it can't infect someone who doesn't already have HBV. When both viruses are present, they can interact in ways that lead to more severe liver disease than either virus would cause alone.

Hepatitis D can be an acute or chronic infection, and it can range from mild to severe, with symptoms similar to those of other types of viral hepatitis, such as jaundice, fatigue, loss of appetite, nausea, vomiting, abdominal pain, and joint pain. In some cases, hepatitis D can lead to serious complications, including liver failure and death.

Hepatitis D is primarily spread through contact with infected blood or other bodily fluids, such as during sexual contact, sharing needles, or mother-to-child transmission during childbirth. It's preventable through vaccination against hepatitis B, which provides immunity to both viruses. There is no specific treatment for hepatitis D, but antiviral therapy for hepatitis B can help manage the infection and prevent complications.

Chronic Hepatitis D is a liver infection caused by the hepatitis delta virus (HDV). It is often considered a serious form of hepatitis because it can lead to more severe liver disease than hepatitis B alone. HDV is a defective virus that requires the presence of hepatitis B surface antigen (HBsAg) to replicate and cause infection. Therefore, chronic hepatitis D only occurs in individuals who have an underlying chronic hepatitis B infection.

Chronic hepatitis D is characterized by persistent inflammation and damage to the liver, which can lead to scarring (fibrosis), cirrhosis, liver failure, and increased risk of liver cancer over time. Symptoms may include fatigue, joint pain, loss of appetite, nausea, vomiting, abdominal pain, dark urine, and jaundice. However, some people with chronic hepatitis D may not have any symptoms until the disease has progressed to a more advanced stage.

Chronic hepatitis D is diagnosed through blood tests that detect HDV antibodies and antigens, as well as liver function tests and imaging studies to assess liver damage. Treatment typically involves antiviral therapy to suppress the replication of both HBV and HDV, as well as supportive care to manage symptoms and prevent complications. In some cases, a liver transplant may be necessary for individuals with advanced liver disease due to chronic hepatitis D.

Hepatitis Delta Virus (HDV) is not a traditional virus but rather a defective RNA particle that requires the assistance of the hepatitis B virus (HBV) to replicate. It's also known as delta agent or hepatitis D. HDV is a unique pathogen that only infects individuals who are already infected with HBV.

The virus causes a more severe form of viral hepatitis than HBV alone, leading to a higher risk of fulminant hepatitis (acute liver failure) and chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma. HDV is primarily transmitted through percutaneous or sexual contact with infected blood or body fluids.

Prevention strategies include vaccination against HBV, which also prevents HDV infection, and avoiding high-risk behaviors such as intravenous drug use and unprotected sex with multiple partners. There is no specific treatment for HDV; however, antiviral therapy for HBV can help manage the infection.

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. The virus is transmitted through contact with infected blood, semen, and other bodily fluids. It can also be passed from an infected mother to her baby at birth.

Acute hepatitis B infection lasts for a few weeks to several months and often causes no symptoms. However, some people may experience mild to severe flu-like symptoms, yellowing of the skin and eyes (jaundice), dark urine, and fatigue. Most adults with acute hepatitis B recover completely and develop lifelong immunity to the virus.

Chronic hepatitis B infection can lead to serious liver damage, including cirrhosis and liver cancer. People with chronic hepatitis B may experience long-term symptoms such as fatigue, joint pain, and depression. They are also at risk for developing liver failure and liver cancer.

Prevention measures include vaccination, safe sex practices, avoiding sharing needles or other drug injection equipment, and covering wounds and skin rashes. There is no specific treatment for acute hepatitis B, but chronic hepatitis B can be treated with antiviral medications to slow the progression of liver damage.

Hepatitis Delta Antigens (HDAg) are proteins found on the surface of the Hepatitis Delta Virus (HDV), a defective virus that requires the assistance of the Hepatitis B Virus (HBV) to replicate. There are two types of HDAg: small (S-HDAg) and large (L-HDAg). S-HDAg is a 195-amino acid protein that is essential for viral replication, while L-HDAg is a 214-amino acid protein that regulates the packaging of the viral genome into new virus particles. The presence of HDAg can be used to diagnose HDV infection and distinguish it from other forms of hepatitis.

Hepatitis B virus (HBV) is a DNA virus that belongs to the Hepadnaviridae family and causes the infectious disease known as hepatitis B. This virus primarily targets the liver, where it can lead to inflammation and damage of the liver tissue. The infection can range from acute to chronic, with chronic hepatitis B increasing the risk of developing serious liver complications such as cirrhosis and liver cancer.

The Hepatitis B virus has a complex life cycle, involving both nuclear and cytoplasmic phases. It enters hepatocytes (liver cells) via binding to specific receptors and is taken up by endocytosis. The viral DNA is released into the nucleus, where it is converted into a covalently closed circular DNA (cccDNA) form, which serves as the template for viral transcription.

HBV transcribes several RNAs, including pregenomic RNA (pgRNA), which is used as a template for reverse transcription during virion assembly. The pgRNA is encapsidated into core particles along with the viral polymerase and undergoes reverse transcription to generate new viral DNA. This process occurs within the cytoplasm of the hepatocyte, resulting in the formation of immature virions containing partially double-stranded DNA.

These immature virions are then enveloped by host cell membranes containing HBV envelope proteins (known as surface antigens) to form mature virions that can be secreted from the hepatocyte and infect other cells. The virus can also integrate into the host genome, which may contribute to the development of hepatocellular carcinoma in chronic cases.

Hepatitis B is primarily transmitted through exposure to infected blood or bodily fluids containing the virus, such as through sexual contact, sharing needles, or from mother to child during childbirth. Prevention strategies include vaccination, safe sex practices, and avoiding needle-sharing behaviors. Treatment for hepatitis B typically involves antiviral medications that can help suppress viral replication and reduce the risk of liver damage.

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It's primarily spread through contact with contaminated blood, often through sharing needles or other equipment to inject drugs. For some people, hepatitis C is a short-term illness but for most — about 75-85% — it becomes a long-term, chronic infection that can lead to serious health problems like liver damage, liver failure, and even liver cancer. The virus can infect and inflame the liver, causing symptoms like jaundice (yellowing of the skin and eyes), abdominal pain, fatigue, and dark urine. Many people with hepatitis C don't have any symptoms, so they might not know they have the infection until they experience complications. There are effective treatments available for hepatitis C, including antiviral medications that can cure the infection in most people. Regular testing is important to diagnose and treat hepatitis C early, before it causes serious health problems.

Hepatitis B Surface Antigens (HBsAg) are proteins found on the surface of the Hepatitis B virus. They are present in the blood of individuals infected with the Hepatitis B virus and are used as a marker for the presence of a current Hepatitis B infection. The detection of HBsAg in the blood indicates that an individual is infectious and can transmit the virus to others. It is typically used in diagnostic tests to detect and diagnose Hepatitis B infections, monitor treatment response, and assess the risk of transmission.

Hepatitis A is a viral infection that specifically targets the liver, causing inflammation and impaired function. This disease is caused by the hepatitis A virus (HAV), which spreads primarily through the fecal-oral route, often due to poor sanitation and hygiene. Individuals can become infected by consuming food or water contaminated with HAV or by coming into direct contact with an infected person's stool.

The symptoms of hepatitis A may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice (yellowing of the skin and eyes). However, in some cases, particularly in children under six years old, the infection may be asymptomatic.

While hepatitis A can be unpleasant and cause serious complications, it is rarely fatal and most people recover completely within a few months. Preventive measures include vaccination, practicing good hygiene, and avoiding potentially contaminated food and water.

Hepatitis viruses refer to a group of viral agents that primarily target the liver, causing inflammation and damage to hepatocytes (liver cells). This results in various clinical manifestations, ranging from an acute infection to a chronic, persistent infection. There are five main types of hepatitis viruses, named Hepatitis A, B, C, D, and E virus, each with distinct genetic material, modes of transmission, and disease severity.

1. Hepatitis A Virus (HAV): This is a single-stranded RNA virus that is primarily transmitted through the fecal-oral route, often via contaminated food or water. Infected individuals may experience symptoms such as jaundice, fatigue, abdominal pain, and loss of appetite. While most people recover completely within a few months, severe complications can occur in rare cases. A vaccine is available to prevent HAV infection.
2. Hepatitis B Virus (HBV): This is a double-stranded DNA virus that is primarily transmitted through contact with infected blood or bodily fluids, such as during sexual contact, sharing needles, or from mother to child during childbirth. HBV can cause both acute and chronic hepatitis, which may lead to severe liver complications like cirrhosis and liver cancer if left untreated. A vaccine is available to prevent HBV infection.
3. Hepatitis C Virus (HCV): This is a single-stranded RNA virus that is primarily transmitted through contact with infected blood, often through sharing needles or during medical procedures using contaminated equipment. Like HBV, HCV can cause both acute and chronic hepatitis, which may lead to severe liver complications if left untreated. No vaccine is currently available for HCV; however, antiviral treatments can cure the infection in many cases.
4. Hepatitis D Virus (HDV): This is a defective RNA virus that requires the presence of HBV to replicate and cause infection. HDV is primarily transmitted through contact with infected blood or bodily fluids, similar to HBV. Co-infection with both HBV and HDV can result in more severe liver disease compared to HBV infection alone. Antiviral treatments are available for HDV; however, a vaccine is not.
5. Hepatitis E Virus (HEV): This is a single-stranded RNA virus that primarily causes acute hepatitis and is usually transmitted through the fecal-oral route, often through contaminated food or water. In most cases, HEV infection resolves on its own without treatment. However, in pregnant women and individuals with weakened immune systems, HEV can cause severe liver complications. No vaccine is currently available for HEV in the United States; however, a vaccine has been approved in some countries.

Hepatitis antibodies are proteins produced by the immune system in response to an infection caused by a hepatitis virus. There are several types of hepatitis viruses, including A, B, C, D, and E, each with their own specific antibodies.

The presence of hepatitis antibodies in the blood can indicate a current or past infection with the corresponding hepatitis virus. For example, the detection of anti-HAV (hepatitis A virus) antibodies indicates a past infection or immunization against hepatitis A, while the detection of anti-HBs (hepatitis B surface antigen) antibodies indicates immunity due to vaccination or recovery from a hepatitis B infection.

It's important to note that some hepatitis antibodies may not provide immunity to future infections, and individuals can still be infected with the virus even if they have previously produced antibodies against it. Therefore, regular testing and vaccination are essential for preventing the spread of hepatitis viruses and protecting public health.

Viral hepatitis in humans refers to inflammation of the liver caused by infection with viruses that primarily target the liver. There are five main types of human viral hepatitis, designated as Hepatitis A, B, C, D, and E virus (HAV, HBV, HCV, HDV, and HEV). These viruses can cause a range of illnesses, from acute self-limiting hepatitis to chronic hepatitis, which can lead to cirrhosis and liver cancer.

1. Hepatitis A virus (HAV) is typically spread through the fecal-oral route, often through contaminated food or water. It usually results in an acute self-limiting infection, but rarely can cause chronic hepatitis in individuals with weakened immune systems.
2. Hepatitis B virus (HBV) is primarily transmitted through contact with infected blood, semen, and other bodily fluids. It can lead to both acute and chronic hepatitis, which may result in cirrhosis and liver cancer if left untreated.
3. Hepatitis C virus (HCV) is predominantly spread through exposure to infected blood, such as through sharing needles or receiving contaminated blood transfusions. Chronic hepatitis C is common, and it can lead to serious liver complications like cirrhosis and liver cancer if not treated.
4. Hepatitis D virus (HDV) is an incomplete virus that requires the presence of HBV for its replication. HDV infection occurs only in individuals already infected with HBV, leading to more severe liver disease compared to HBV monoinfection.
5. Hepatitis E virus (HEV) is primarily transmitted through the fecal-oral route, often through contaminated food or water. It usually results in an acute self-limiting infection but can cause chronic hepatitis in pregnant women and individuals with weakened immune systems.

Prevention measures include vaccination for HAV and HBV, safe sex practices, avoiding sharing needles, and ensuring proper hygiene and sanitation to prevent fecal-oral transmission.

Hepatitis antigens are proteins or molecules present on the surface or inside the hepatitis viruses (hepatitis A, B, C, D, and E) that can stimulate an immune response in the body. These antigens are targeted by the immune system to produce antibodies to fight against the infection.

For example, the Hepatitis B surface antigen (HBsAg) is a protein found on the surface of the hepatitis B virus and its presence in the blood indicates an ongoing infection or evidence of past infection/vaccination. Similarly, the core antigen (HBcAg) is a protein found inside the hepatitis B virus and is a marker of active viral replication.

Detection of these antigens in clinical samples such as blood is useful for diagnosing hepatitis infections and monitoring the effectiveness of treatment.

Hepatitis B core antigen (HBcAg) is a protein found in the core of the hepatitis B virus (HBV). It is present during active replication of the virus and plays a crucial role in the formation of the viral capsid or core. The antibodies produced against HBcAg (anti-HBc) can be detected in the blood, which serves as a marker for current or past HBV infection. It is important to note that HBcAg itself is not detectable in the blood because it is confined within the viral particle. However, during the serological testing of hepatitis B, the detection of anti-HBc IgM indicates a recent acute infection, while the presence of anti-HBc IgG suggests either a past resolved infection or an ongoing chronic infection.

Hepatitis B antigens are proteins or particles present on the surface (HBsAg) or inside (HBcAg, HBeAg) the hepatitis B virus.

1. HBsAg (Hepatitis B surface antigen): This is a protein found on the outer surface of the hepatitis B virus. Its presence in the blood indicates an active infection with hepatitis B virus. It's also used as a marker to diagnose hepatitis B infection and monitor treatment response.

2. HBcAg (Hepatitis B core antigen): This is a protein found inside the hepatitis B virus core. It's not usually detected in the blood, but its antibodies (anti-HBc) are used to diagnose past or present hepatitis B infection.

3. HBeAg (Hepatitis B e antigen): This is a protein found inside the hepatitis B virus core and is associated with viral replication. Its presence in the blood indicates high levels of viral replication, increased infectivity, and higher risk of liver damage. It's used to monitor disease progression and treatment response.

These antigens play a crucial role in the diagnosis, management, and prevention of hepatitis B infection.

Hepatitis is a medical condition characterized by inflammation of the liver, often resulting in damage to liver cells. It can be caused by various factors, including viral infections (such as Hepatitis A, B, C, D, and E), alcohol abuse, toxins, medications, and autoimmune disorders. Symptoms may include jaundice, fatigue, abdominal pain, loss of appetite, nausea, vomiting, and dark urine. The severity of the disease can range from mild illness to severe, life-threatening conditions, such as liver failure or cirrhosis.

Chronic Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that lasts for more than six months. This long-term infection can lead to scarring of the liver (cirrhosis), which can cause serious health problems, such as liver failure or liver cancer, in some individuals. The infection is usually asymptomatic until complications arise, but it can be detected through blood tests that identify antibodies to the virus or viral RNA. Chronic hepatitis C is typically managed with antiviral therapy, which can help clear the virus from the body and reduce the risk of liver damage.

Chronic Hepatitis B is a persistent infection of the liver caused by the hepatitis B virus (HBV), which can lead to chronic inflammation and scarring of the liver over time. It is defined as the presence of hepatitis B surface antigen (HBsAg) in the blood for more than six months.

The infection can be asymptomatic or may cause nonspecific symptoms such as fatigue, loss of appetite, nausea, and joint pain. A small percentage of people with chronic HBV infection may develop serious complications, including cirrhosis, liver failure, and liver cancer. Treatment options for chronic hepatitis B include antiviral medications that can help to suppress the virus and reduce the risk of liver damage. Vaccination is available to prevent hepatitis B infection.

Hepatitis A virus (HAV) is the causative agent of hepatitis A, a viral infection that causes inflammation of the liver. It is a small, non-enveloped, single-stranded RNA virus belonging to the Picornaviridae family and Hepatovirus genus. The virus primarily spreads through the fecal-oral route, often through contaminated food or water, or close contact with an infected person. After entering the body, HAV infects hepatocytes in the liver, leading to liver damage and associated symptoms such as jaundice, fatigue, abdominal pain, and nausea. The immune system eventually clears the infection, providing lifelong immunity against future HAV infections. Preventive measures include vaccination and practicing good hygiene to prevent transmission.

"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.

The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.

It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."

Superinfection is a medical term that refers to a secondary infection which occurs during or following the treatment of an initial infection. This second infection is often caused by a different microorganism that is resistant to the medication used to treat the first infection. Superinfections can occur in various parts of the body, such as the skin, respiratory system, gastrointestinal tract, or urinary tract, and are more common in individuals with weakened immune systems, chronic illnesses, or those who have been on antibiotics for an extended period.

Superinfections can lead to more severe complications, prolonged hospital stays, increased healthcare costs, and higher mortality rates if not promptly diagnosed and treated appropriately. Healthcare providers must be vigilant in monitoring patients' responses to treatment and recognizing signs of superinfection, such as worsening symptoms or the development of new ones, to ensure timely intervention and optimal patient outcomes.

Hepatitis B antibodies are proteins produced by the immune system in response to the presence of the Hepatitis B virus. There are two main types of Hepatitis B antibodies:

1. Hepatitis B surface antibody (anti-HBs): This is produced when a person has recovered from a Hepatitis B infection or has been successfully vaccinated against the virus. The presence of anti-HBs indicates immunity to Hepatitis B.
2. Hepatitis B core antibody (anti-HBC): This is produced during a Hepatitis B infection and remains present for life, even after the infection has been cleared. However, the presence of anti-HBC alone does not indicate immunity to Hepatitis B, as it can also be present in people who have a chronic Hepatitis B infection.

It's important to note that testing for Hepatitis B antibodies is typically done through blood tests and can help determine whether a person has been infected with the virus, has recovered from an infection, or has been vaccinated against it.

Chronic hepatitis is a type of liver inflammation that lasts for more than six months and can lead to scarring of the liver (cirrhosis), liver failure, and even liver cancer in some cases. It can be caused by various factors, including viral infections such as Hepatitis B and C, autoimmune disorders, alcohol abuse, and non-alcoholic fatty liver disease. The symptoms of chronic hepatitis may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, joint pain, dark urine, and jaundice (yellowing of the skin and eyes). Treatment for chronic hepatitis depends on the underlying cause and may include antiviral medications, immunosuppressive drugs, or lifestyle changes.

Hepatitis A vaccines are inactivated or live attenuated viral vaccines that are administered to prevent infection and illness caused by the hepatitis A virus. The vaccine contains antigens that stimulate an immune response in the body, leading to the production of antibodies that protect against future infection with the virus.

The inactivated hepatitis A vaccine is made from viruses that have been chemically treated to destroy their ability to cause disease while preserving their ability to stimulate an immune response. This type of vaccine is typically given in two doses, six months apart, and provides long-term protection against the virus.

The live attenuated hepatitis A vaccine contains a weakened form of the virus that is unable to cause illness but can still stimulate an immune response. This type of vaccine is given as a single dose and provides protection against the virus for at least 20 years.

Hepatitis A vaccines are recommended for people who are at increased risk of infection, including travelers to areas where hepatitis A is common, men who have sex with men, people who use injection drugs, and people with chronic liver disease or clotting factor disorders. The vaccine is also recommended for children in certain states and communities where hepatitis A is endemic.

Hepacivirus is a genus of viruses in the family Flaviviridae. The most well-known member of this genus is Hepatitis C virus (HCV), which is a major cause of liver disease worldwide. HCV infection can lead to chronic hepatitis, cirrhosis, and liver cancer.

Hepaciviruses are enveloped viruses with a single-stranded, positive-sense RNA genome. They have a small icosahedral capsid and infect a variety of hosts, including humans, non-human primates, horses, and birds. The virus enters the host cell by binding to specific receptors on the cell surface and is then internalized through endocytosis.

HCV has a high degree of genetic diversity and is classified into seven major genotypes and numerous subtypes based on differences in its RNA sequence. This genetic variability can affect the virus's ability to evade the host immune response, making treatment more challenging.

In addition to HCV, other hepaciviruses have been identified in various animal species, including equine hepacivirus (EHCV), rodent hepacivirus (RHV), and bat hepacivirus (BtHepCV). These viruses are being studied to better understand the biology of hepaciviruses and their potential impact on human health.

Hepatitis B e antigen (HBeAg) is a protein produced by the hepatitis B virus (HBV) during its replication process. It can be found in the blood of individuals infected with HBV. The presence of HBeAg generally indicates that the virus is actively replicating in the liver and that the individual has high levels of viral load.

HBeAg is a serological marker used to assess the severity and activity of HBV infection, as well as the response to antiviral treatment. In particular, the disappearance of HBeAg from the blood (known as seroconversion) is often associated with a decrease in viral replication and an improvement in liver disease. However, the presence of HBeAg does not necessarily mean that the individual will develop symptoms or liver damage, as some people can remain asymptomatic carriers of the virus for many years.

It's important to note that not all HBV strains produce HBeAg, and some mutant strains may not produce detectable levels of this antigen even when the virus is actively replicating. Therefore, additional tests may be needed to confirm the presence or absence of HBV infection in these cases.

Antiviral agents are a class of medications that are designed to treat infections caused by viruses. Unlike antibiotics, which target bacteria, antiviral agents interfere with the replication and infection mechanisms of viruses, either by inhibiting their ability to replicate or by modulating the host's immune response to the virus.

Antiviral agents are used to treat a variety of viral infections, including influenza, herpes simplex virus (HSV) infections, human immunodeficiency virus (HIV) infection, hepatitis B and C, and respiratory syncytial virus (RSV) infections.

These medications can be administered orally, intravenously, or topically, depending on the type of viral infection being treated. Some antiviral agents are also used for prophylaxis, or prevention, of certain viral infections.

It is important to note that antiviral agents are not effective against all types of viruses and may have significant side effects. Therefore, it is essential to consult with a healthcare professional before starting any antiviral therapy.

Hepatitis E is a viral infection that specifically affects the liver, caused by the hepatitis E virus (HEV). The disease is primarily transmitted through the fecal-oral route, often through contaminated water or food. It can also be spread through blood transfusions and vertical transmission from mother to fetus.

The incubation period for hepatitis E ranges from 2 to 10 weeks. Symptoms of the disease are similar to other types of viral hepatitis and may include jaundice (yellowing of the skin and eyes), fatigue, loss of appetite, abdominal pain, nausea, vomiting, joint pain, and dark urine.

In most cases, hepatitis E is a self-limiting disease, meaning that it resolves on its own within a few weeks to months. However, in some individuals, particularly those with weakened immune systems, the infection can lead to severe complications such as acute liver failure and death. Pregnant women, especially those in the third trimester, are at higher risk of developing severe disease and have a mortality rate of up to 25%.

Prevention measures include maintaining good hygiene practices, practicing safe food handling and preparation, and ensuring access to clean water sources. Currently, there is no specific treatment for hepatitis E, but supportive care can help manage symptoms. Vaccines are available in some countries to prevent the disease.

A viral RNA (ribonucleic acid) is the genetic material found in certain types of viruses, as opposed to viruses that contain DNA (deoxyribonucleic acid). These viruses are known as RNA viruses. The RNA can be single-stranded or double-stranded and can exist as several different forms, such as positive-sense, negative-sense, or ambisense RNA. Upon infecting a host cell, the viral RNA uses the host's cellular machinery to translate the genetic information into proteins, leading to the production of new virus particles and the continuation of the viral life cycle. Examples of human diseases caused by RNA viruses include influenza, COVID-19 (SARS-CoV-2), hepatitis C, and polio.

Hepatitis C antibodies are proteins produced by the immune system in response to an infection with the hepatitis C virus (HCV). Detection of these antibodies in the blood indicates a past or present HCV infection. However, it does not necessarily mean that the person is currently infected, as antibodies can persist for years even after the virus has been cleared from the body. Additional tests are usually needed to confirm whether the infection is still active and to guide treatment decisions.

Hepatitis E virus (HEV) is a single-stranded, positive-sense RNA virus that belongs to the family Hepeviridae and genus Orthohepevirus. It primarily infects the liver, causing acute hepatitis in humans. The virus is transmitted through the fecal-oral route, often through contaminated water or food sources. Ingestion of raw or undercooked pork or deer meat can also lead to HEV infection.

HEV infection typically results in self-limiting acute hepatitis, characterized by symptoms such as jaundice, fatigue, loss of appetite, abdominal pain, and dark urine. In some cases, particularly among pregnant women and individuals with weakened immune systems, HEV infection can lead to severe complications, including fulminant hepatic failure and death.

There are four main genotypes of HEV that infect humans: genotype 1 and 2 are primarily found in developing countries and are transmitted through contaminated water; genotype 3 and 4 are found worldwide and can be transmitted through both zoonotic and human-to-human routes.

Prevention measures include improving sanitation, access to clean water, and food safety practices. Currently, there is no specific antiviral treatment for HEV infection, but supportive care can help manage symptoms. A vaccine against HEV is available in China and has shown efficacy in preventing the disease.

Hepatitis A antibodies are proteins produced by the immune system in response to a Hepatitis A virus infection or after vaccination. There are two types of Hepatitis A antibodies:

1. IgM anti-HAV (Hepatitis A Virus) antibodies: These are the first type of antibodies produced by the immune system during a Hepatitis A infection. They appear in the blood within 2 to 4 weeks after exposure to the virus and remain detectable for up to 12 weeks. The presence of IgM anti-HAV antibodies indicates a recent or ongoing Hepatitis A infection.

2. IgG anti-HAV antibodies: These are the second type of antibodies produced by the immune system during a Hepatitis A infection, and they appear in the blood several weeks after the onset of illness. IgG anti-HAV antibodies remain detectable for many years, providing long-term immunity against future Hepatitis A infections. After vaccination, only IgG anti-HAV antibodies are produced, indicating immunity to Hepatitis A.

Testing for Hepatitis A antibodies is used to diagnose acute or past Hepatitis A infections and to assess immunity following vaccination.

I'm sorry for any confusion, but "Viral Hepatitis, Animal" is not a standard medical classification or definition. Hepatitis refers to inflammation of the liver, and viral hepatitis refers to inflammation caused by a virus. The term "animal" in this context doesn't provide a clear meaning.

However, it's worth noting that some animals can contract viral hepatitis, similar to humans. For instance, there are hepatitis A, B, and C-like viruses that have been identified in various animal species. These are typically not transmissible to humans.

If you're referring to a specific medical condition or context, could you please provide more details? I'd be happy to help further with more information.

Autoimmune hepatitis is a chronic (long-term) disease in which the body's immune system mistakenly attacks the liver, leading to inflammation and damage. This results in decreased liver function over time if not treated. The exact cause of autoimmune hepatitis is unknown, but it is believed to be associated with genetic factors and exposure to certain environmental triggers, such as viral infections or medications.

There are two main types of autoimmune hepatitis:

1. Type 1 (classic) autoimmune hepatitis: This form can affect both adults and children, and it is more common in women than men. People with this type may also have other autoimmune disorders, such as rheumatoid arthritis, thyroid disease, or ulcerative colitis.
2. Type 2 autoimmune hepatitis: This form primarily affects children and young women. It is less common than type 1 and tends to be more severe. People with this type may also have other autoimmune disorders, such as celiac disease or chronic candidiasis.

Symptoms of autoimmune hepatitis can vary widely, from mild to severe. They may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, joint pain, jaundice (yellowing of the skin and eyes), dark urine, and light-colored stools.

Diagnosis typically involves blood tests, imaging studies, and sometimes a liver biopsy to assess the extent of damage. Treatment usually includes medications that suppress the immune system, such as corticosteroids and immunosuppressants, which can help reduce inflammation and slow or stop liver damage. In some cases, lifestyle changes and supportive care may also be necessary.

Hepatitis A Virus, Human (HAV): A single-stranded, positive-sense RNA virus belonging to the Picornaviridae family, specifically the Hepatovirus genus. It is the causative agent of Hepatitis A, a viral infection that primarily affects the liver. The virus is typically transmitted through the fecal-oral route, often via contaminated food or water, or close contact with an infected individual. Following incubation (15-50 days), symptoms may include jaundice, fatigue, abdominal pain, loss of appetite, nausea, diarrhea, and fever. Most people recover completely within a few weeks; however, severe complications and death are possible, especially in individuals with preexisting liver disease. Prevention is primarily achieved through vaccination and practicing good hygiene.

I'm sorry for any confusion, but "Animal Hepatitis" is not a medical term used to describe a specific disease. Hepatitis refers to inflammation of the liver, and it can be caused by various factors, including viruses, alcohol, drugs, and certain medical conditions.

However, there are several viral hepatitis types that can infect animals, such as Hepatitis A, B, and C, which primarily affect humans. But there are also other hepatitis viruses that are species-specific and primarily infect animals, such as:

1. Canine Hepatitis (Adenovirus Type 1): This is a viral infection that affects dogs and causes liver damage, respiratory signs, and occasionally death.
2. Feline Infectious Peritonitis (FIP) Virus: While not strictly a hepatitis virus, this feline coronavirus can cause severe inflammation of the liver and other organs in cats.
3. Equine Infectious Anemia Virus (EIAV): This retrovirus affects horses and causes cyclic fever, anemia, and occasionally liver disease.
4. Avian Hepatitis E Virus: A recently discovered virus that infects birds and can cause hepatitis and other systemic signs in chickens and other avian species.

If you're looking for information on a specific animal hepatitis virus or a different medical term, please provide more context so I can give you a more accurate answer.

Viral hepatitis vaccines are vaccines that prevent infection caused by various hepatitis viruses, including hepatitis A and B. These vaccines contain antigens that stimulate the immune system to produce antibodies that protect against infection with the corresponding virus. The vaccines are typically administered through injection and may require multiple doses for full protection.

The hepatitis A vaccine is made from inactivated hepatitis A virus, while the hepatitis B vaccine is made from recombinant hepatitis B surface antigen. Both vaccines have been shown to be highly effective in preventing infection and reducing the risk of complications associated with viral hepatitis, such as liver disease and liver cancer.

It's important to note that there are no vaccines available for other types of viral hepatitis, such as hepatitis C, D, or E. Prevention strategies for these types of viral hepatitis typically involve measures to reduce exposure to the virus, such as safe injection practices and avoiding high-risk behaviors like sharing needles or having unprotected sex with infected individuals.

Genotype, in genetics, refers to the complete heritable genetic makeup of an individual organism, including all of its genes. It is the set of instructions contained in an organism's DNA for the development and function of that organism. The genotype is the basis for an individual's inherited traits, and it can be contrasted with an individual's phenotype, which refers to the observable physical or biochemical characteristics of an organism that result from the expression of its genes in combination with environmental influences.

It is important to note that an individual's genotype is not necessarily identical to their genetic sequence. Some genes have multiple forms called alleles, and an individual may inherit different alleles for a given gene from each parent. The combination of alleles that an individual inherits for a particular gene is known as their genotype for that gene.

Understanding an individual's genotype can provide important information about their susceptibility to certain diseases, their response to drugs and other treatments, and their risk of passing on inherited genetic disorders to their offspring.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Murine hepatitis virus (MHV) is a type of coronavirus that primarily infects laboratory mice. It is not related to the human hepatitis viruses A, B, C, D, or E. MHV causes a range of diseases in mice, including hepatitis (liver inflammation), encephalomyelitis (inflammation of the brain and spinal cord), and enteritis (inflammation of the intestine). The virus is transmitted through fecal-oral route and respiratory droplets. It's widely used in research to understand the pathogenesis, immunity, and molecular biology of coronaviruses.

A chronic disease is a long-term medical condition that often progresses slowly over a period of years and requires ongoing management and care. These diseases are typically not fully curable, but symptoms can be managed to improve quality of life. Common chronic diseases include heart disease, stroke, cancer, diabetes, arthritis, and COPD (chronic obstructive pulmonary disease). They are often associated with advanced age, although they can also affect children and younger adults. Chronic diseases can have significant impacts on individuals' physical, emotional, and social well-being, as well as on healthcare systems and society at large.

Hepatitis C antigens refer to the proteins present on the surface of the hepatitis C virus (HCV). The most commonly studied and clinically relevant antigen is the core protein, which plays a crucial role in the viral replication process. Detection of HCV antigens in serum or plasma can indicate an ongoing infection, as they appear during the early stages of infection and usually persist until the development of a humoral immune response, which leads to the production of antibodies against these antigens.

The detection of HCV core antigen (HCVcAg) has been used as an alternative diagnostic marker for HCV infection, especially in resource-limited settings where nucleic acid testing (NAT), such as polymerase chain reaction (PCR) for HCV RNA, might not be readily available. However, the sensitivity and specificity of HCVcAg detection are generally lower than those of NAT methods. Nonetheless, it remains a valuable tool in monitoring treatment response and disease progression in individuals with chronic hepatitis C infection.

Hepatovirus is a genus of viruses in the Picornaviridae family, and it's most notably represented by the Human Hepatitis A Virus (HAV). These viruses are non-enveloped, with a single-stranded, positive-sense RNA genome. They primarily infect hepatocytes, causing liver inflammation and disease, such as hepatitis. Transmission of hepatoviruses typically occurs through the fecal-oral route, often via contaminated food or water. The virus causes an acute infection that does not usually become chronic, and recovery is usually complete within a few weeks. Immunity after infection is solid and lifelong.

Prevalence, in medical terms, refers to the total number of people in a given population who have a particular disease or condition at a specific point in time, or over a specified period. It is typically expressed as a percentage or a ratio of the number of cases to the size of the population. Prevalence differs from incidence, which measures the number of new cases that develop during a certain period.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Liver cirrhosis is a chronic, progressive disease characterized by the replacement of normal liver tissue with scarred (fibrotic) tissue, leading to loss of function. The scarring is caused by long-term damage from various sources such as hepatitis, alcohol abuse, nonalcoholic fatty liver disease, and other causes. As the disease advances, it can lead to complications like portal hypertension, fluid accumulation in the abdomen (ascites), impaired brain function (hepatic encephalopathy), and increased risk of liver cancer. It is generally irreversible, but early detection and treatment of underlying causes may help slow down its progression.

Interferon-alpha (IFN-α) is a type I interferon, which is a group of signaling proteins made and released by host cells in response to the presence of viruses, parasites, and tumor cells. It plays a crucial role in the immune response against viral infections. IFN-α has antiviral, immunomodulatory, and anti-proliferative effects.

IFN-α is produced naturally by various cell types, including leukocytes (white blood cells), fibroblasts, and epithelial cells, in response to viral or bacterial stimulation. It binds to specific receptors on the surface of nearby cells, triggering a signaling cascade that leads to the activation of genes involved in the antiviral response. This results in the production of proteins that inhibit viral replication and promote the presentation of viral antigens to the immune system, enhancing its ability to recognize and eliminate infected cells.

In addition to its role in the immune response, IFN-α has been used as a therapeutic agent for various medical conditions, including certain types of cancer, chronic hepatitis B and C, and multiple sclerosis. However, its use is often limited by side effects such as flu-like symptoms, depression, and neuropsychiatric disorders.

Hepatitis A antigens refer to the proteins or molecules present on the surface of the Hepatitis A virus (HAV) that can stimulate an immune response in the body. There are two main types of HAV antigens:

1. Hepatitis A Virus Capsid Antigen (also known as HAV VP1): This is a structural protein that makes up the outer shell or capsid of the HAV particle. It contains several epitopes (regions that can be recognized by the immune system) that can induce the production of antibodies in infected individuals.
2. Hepatitis A Virus Non-structural Antigen (also known as HAV NS1): This is a non-structural protein produced during the replication of the HAV genome. It plays a crucial role in the replication and assembly of new HAV particles, but it is not present in the mature virion. However, its detection in serum or liver tissue can indicate an ongoing HAV infection.

The presence of antibodies against these antigens (anti-HAV antibodies) in a person's blood can be used to diagnose past or recent Hepatitis A infections and immunity acquired through vaccination.

Alcoholic hepatitis is a medical condition characterized by inflammation and damage to the liver caused by excessive alcohol consumption. It is a type of hepatitis that specifically results from alcohol abuse, rather than from viral infections or other causes. The condition can vary in severity, and long-term heavy drinking increases the risk of developing alcoholic hepatitis.

The inflammation in alcoholic hepatitis can lead to symptoms such as jaundice (yellowing of the skin and eyes), abdominal pain, nausea, vomiting, loss of appetite, and fever. In severe cases, it can cause liver failure, which may be life-threatening. Treatment typically involves alcohol abstinence, supportive care, and medications to manage symptoms and prevent further liver damage. In some cases, hospitalization and more intensive treatments may be necessary.

Ribavirin is an antiviral medication used in the treatment of certain viral infections, including hepatitis C and respiratory syncytial virus (RSV) infection. It works by interfering with viral replication, preventing the virus from multiplying within infected cells. Ribavirin is often used in combination with other antiviral drugs for more effective treatment.

It's important to note that ribavirin can have serious side effects and should only be used under the supervision of a healthcare professional. Additionally, it is not effective against all types of viral infections and its use should be based on a confirmed diagnosis and appropriate medical evaluation.

Duck hepatitis B virus (DHBV) is not a medical definition related to human health, but it is a species of hepatitis B virus that primarily infects various species of ducks and other Anseriformes (waterfowl). It is closely related to the human hepatitis B virus (HBV), but it is not known to infect humans or other mammals.

DHBV, like HBV, is a DNA virus that targets the liver and can cause both acute and chronic infections. The virus is transmitted through the fecal-oral route and primarily affects young ducklings. Infection with DHBV can lead to liver damage and death in infected birds.

Researchers study DHBV as a model system for understanding HBV infection and pathogenesis, due to their similarities in viral structure, replication strategy, and host-virus interactions. However, it is important to note that DHBV is not a human health concern and does not pose a risk of infection to humans or other mammals.

Alanine transaminase (ALT) is a type of enzyme found primarily in the cells of the liver and, to a lesser extent, in the cells of other tissues such as the heart, muscles, and kidneys. Its primary function is to catalyze the reversible transfer of an amino group from alanine to another alpha-keto acid, usually pyruvate, to form pyruvate and another amino acid, usually glutamate. This process is known as the transamination reaction.

When liver cells are damaged or destroyed due to various reasons such as hepatitis, alcohol abuse, nonalcoholic fatty liver disease, or drug-induced liver injury, ALT is released into the bloodstream. Therefore, measuring the level of ALT in the blood is a useful diagnostic tool for evaluating liver function and detecting liver damage. Normal ALT levels vary depending on the laboratory, but typically range from 7 to 56 units per liter (U/L) for men and 6 to 45 U/L for women. Elevated ALT levels may indicate liver injury or disease, although other factors such as muscle damage or heart disease can also cause elevations in ALT.

Viral DNA refers to the genetic material present in viruses that consist of DNA as their core component. Deoxyribonucleic acid (DNA) is one of the two types of nucleic acids that are responsible for storing and transmitting genetic information in living organisms. Viruses are infectious agents much smaller than bacteria that can only replicate inside the cells of other organisms, called hosts.

Viral DNA can be double-stranded (dsDNA) or single-stranded (ssDNA), depending on the type of virus. Double-stranded DNA viruses have a genome made up of two complementary strands of DNA, while single-stranded DNA viruses contain only one strand of DNA.

Examples of dsDNA viruses include Adenoviruses, Herpesviruses, and Poxviruses, while ssDNA viruses include Parvoviruses and Circoviruses. Viral DNA plays a crucial role in the replication cycle of the virus, encoding for various proteins necessary for its multiplication and survival within the host cell.

Viral nonstructural proteins (NS) are viral proteins that are not part of the virion structure. They play various roles in the viral life cycle, such as replication of the viral genome, transcription, translation regulation, and modulation of the host cell environment to favor virus replication. These proteins are often produced in large quantities during infection and can manipulate or disrupt various cellular pathways to benefit the virus. They may also be involved in evasion of the host's immune response. The specific functions of viral nonstructural proteins vary depending on the type of virus.

The liver is a large, solid organ located in the upper right portion of the abdomen, beneath the diaphragm and above the stomach. It plays a vital role in several bodily functions, including:

1. Metabolism: The liver helps to metabolize carbohydrates, fats, and proteins from the food we eat into energy and nutrients that our bodies can use.
2. Detoxification: The liver detoxifies harmful substances in the body by breaking them down into less toxic forms or excreting them through bile.
3. Synthesis: The liver synthesizes important proteins, such as albumin and clotting factors, that are necessary for proper bodily function.
4. Storage: The liver stores glucose, vitamins, and minerals that can be released when the body needs them.
5. Bile production: The liver produces bile, a digestive juice that helps to break down fats in the small intestine.
6. Immune function: The liver plays a role in the immune system by filtering out bacteria and other harmful substances from the blood.

Overall, the liver is an essential organ that plays a critical role in maintaining overall health and well-being.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults. It originates from the hepatocytes, which are the main functional cells of the liver. This type of cancer is often associated with chronic liver diseases such as cirrhosis caused by hepatitis B or C virus infection, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and aflatoxin exposure.

The symptoms of HCC can vary but may include unexplained weight loss, lack of appetite, abdominal pain or swelling, jaundice, and fatigue. The diagnosis of HCC typically involves imaging tests such as ultrasound, CT scan, or MRI, as well as blood tests to measure alpha-fetoprotein (AFP) levels. Treatment options for Hepatocellular carcinoma depend on the stage and extent of the cancer, as well as the patient's overall health and liver function. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or liver transplantation.

Hepatitis B virus (Woodchuck) refers to the hepadnavirus that naturally infects North American woodchucks (Marmota monax). This virus is closely related to the human Hepatitis B virus (HBV), and it is used as a model for studying HBV infection and related liver diseases in woodchucks. The woodchuck hepatitis virus (WHV) can cause both acute and chronic hepatitis, liver fibrosis, cirrhosis, and liver cancer in its natural host. The virus-host interactions and the disease progression in woodchucks closely mimic those observed in humans with HBV infection. Therefore, studies of WHV infection in woodchucks have contributed significantly to our understanding of HBV biology, host immune responses, and the development of novel therapies for HBV infection in humans.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

2020 Viral Hepatitis Surveillance Report , CDC. *Trends and Characteristics in Maternal Hepatitis C Virus Infection Rates ... QuickStats: Prevalence of Past or Present Infection with Hepatitis B Virus Among Adults Aged ≥18 Years, by Race and Hispanic ... Centers for Disease Control and Prevention: Viral Hepatitis. *National Institute for Allergy and Infectious Diseases: Viral ... QuickStats: Percentage of Adults Aged ≥18 Years with Current Hepatitis C Virus Infection, by Health Insurance Coverage - ...
... hepatitis means inflammation of the liver. There are five main hepatitis viruses (A, B, C, D or E). Learn about the different ... Hepatitis B, hepatitis C, and hepatitis D spread through contact with the blood of someone who has the disease. Hepatitis B and ... How is viral hepatitis spread?. Hepatitis A and hepatitis E usually spread through contact with food or water that was ... What causes hepatitis?. There are different types of hepatitis, with different causes:. *Viral hepatitis is the most common ...
... hepatitis C symptoms and hepatitis C treatment. Read about hepatitis C transmission, hepatitis C tests, hepatitis C vaccine, ... Hepatitis C : Review clinical reference information, guidelines, and medical news on hepatitis C-- ... No Need to Restrict Hep C DAA Therapy Based on Alcohol Use ... Pediatric Hepatitis C * Perioperative Management of the Patient ...
The hepatitis C virus (HCV) is a major cause of both acute and chronic hepatitis. ... High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C ... Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. ... Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. ...
Hepatitis E is caused by hepatitis E virus (HEV), a spherical, nonenveloped, single-stranded, single-serotype, RNA virus ... Due to the lack of systematic surveillance for hepatitis E, the incidence and characteristics of hepatitis E cases in the ... Acute hepatitis E is diagnosed by detecting HEV IgM in serum. Detecting HEV RNA in serum or stool specimens further confirms ... Treatment for acute hepatitis E is supportive care. Oral ribavirin has been shown to be effective in the treatment of chronic ...
... Prevention. How great is the risk for hepatitis B?. You may be at risk for hepatitis B if you:. How is hepatitis B ... If you had hepatitis A, it is still possible to get hepatitis B. If you had hepatitis C, another form of hepatitis that can be ... Can hepatitis B be spread by food?. Unlike hepatitis A, another form of hepatitis, hepatitis B is not spread through food or ... Can hepatitis B be spread by food?. What is the hepatitis B carrier state?. What are the symptoms of hepatitis B?. How serious ...
LBXHA - Hepatitis A antibody. Variable Name: LBXHA SAS Label: Hepatitis A antibody. English Text: Hepatitis A antibody. Target ... New immunization strategies have been developed to eliminate the spread of the hepatitis B virus (HBV) and the hepatitis A ... Reported results for all assays meet the Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and ... Hepatitis A (HEPA_H) Data File: HEPA_H.xpt First Published: October 2015. Last Revised: NA ...
World Health Statistics data visualizations ...
Enable Javascript support in the browser ...
Enable Javascript support in the browser ...
Hepatitis A and E. Viral hepatitis is a group of viruses (hepatitis A, B, C, the rarer type D, and E) that can cause both acute ... In rare cases, acute hepatitis E can lead to acute liver failure (fulminant hepatitis) and death. Pregnant women with hepatitis ... Hepatitis A. Hepatitis A causes mild to severe illness in an estimated 1.4 million people per year, with a further 113 million ... The Hepatitis E virus has at least four different genotypes, of which two have been found only in humans. While hepatitis E ...
Acute hepatitis E - Nigeria - http://www.who.int/csr/don/12-july-2017-hepatitis-e-nigeria/en/ ...
Viral hepatitis is caused by five different viruses (hepatitis A, B, C, D, and E). Hepatitis A and hepatitis E behave similarly ... In the Mediterranean, hepatitis D is predominant among hepatitis B virus co-infected people. Similar to Hepatitis A, hepatitis ... and are self-limiting illnesses that do not lead to chronic hepatitis. Hepatitis B, hepatitis C, and hepatitis D are ... Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co-infection. In ...
CDC works with partners to respond to viral hepatitis outbreaks, conducting serologic and molecular testing on clinical samples ... Hepatitis A Outbreaksplus icon *Outbreaks of hepatitis A across the United Statesplus icon *Frequently Asked Questions: ... Hawaii outbreak of hepatitis A - 2016. *Multistate outbreak of hepatitis A virus infections - 2013plus icon *Recall and Advice ... Interim outbreak-specific guidance on hepatitis A vaccine administration. *Outbreaks of hepatitis A are occurring across the ...
Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA) ... Cost Analysis of Single-Dose Hepatitis B Revaccination Among Infants Born to Hepatitis B Surface Antigen-Positive Mothers and ... Hepatitis C Virus Antibody Testing Among 13-to 21-Year-Olds in a Large Sample of US Federally Qualified Health Centers. Jama. ... Perinatal transmission of hepatitis C virus: defining the cascade of care The Journal of pediatrics. 2018 Dec 1;203:34-40. ...
Hepatitis B virus (HBV) infection in a pregnant person poses a serious risk to their infant at birth. ... Perinatal hepatitis B Hepatitis B virus (HBV) infection in a pregnant person poses a serious risk to their infant at birth. ... Pregnant persons should be tested for evidence of hepatitis B virus (HBV) infection, specifically hepatitis B surface antigen ( ... Perinatal hepatitis B * …. This page is located more than 3 levels deep within a topic. Some page levels are currently hidden. ...
... and treatment of autoimmune hepatitis, a disease in which your immune system attacks the liver, causing inflammation and damage ... Autoimmune Hepatitis. View or Print All Sections Definition & Facts Autoimmune hepatitis is a chronic disease in which your ... Many people with autoimmune hepatitis have no symptoms. Experts arent sure what causes autoimmune hepatitis. ... Doctors diagnose autoimmune hepatitis based on a combination of information from your medical history, a physical exam, blood ...
The hepatitis C virus (HCV) spreads through blood or other body fluids, and can lead to cirrhosis or liver cancer. The most ... Hepatitis C. What Is Hepatitis C?. Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). It can lead ... How Do Acute Hepatitis C and Chronic Hepatitis C Differ?. Doctors refer to hepatitis C infections as either acute or chronic:. ... What Problems Can Hepatitis C Cause?. Hepatitis C is the most serious type of hepatitis. Its now one of the most common ...
... diagnosis and treatment for patients with all phases of hepatitis B infection. ... The Hepatitis B Clinic at Massachusetts General Hospital offers comprehensive evaluation, ... Hepatitis B infection can exist in a variety of states, and some of them dont need treatment. However, anyone with hepatitis B ... Hepatitis B Clinic. The Hepatitis B Clinic at Massachusetts General Hospital offers comprehensive evaluation, diagnosis and ...
Posts about Hepatitis written by What Doctors Dont Tell You ... QUESTIONS FROM READERS:HIV AND HEPATITIS VACCINE. What Doctors ... A recent issue of GP (22 May) exhorted all doctors to go get their hep B shots. In a perfect example of the old adage that ... VACCINE LINKED TO MS:New study confirms worst suspicions over the hepatitis B jab. What Doctors Dont Tell You ... Besides the possibility of contracting AIDS or hepatitis, blood transfusion carries a host of other risks, perhaps even aiding ...
Find out about the different types of hepatitis. ... Hepatitis, an infectious liver disease, is more contagious than ... The three most common hepatitis viruses are hepatitis A, hepatitis B, and hepatitis C. (Hepatitis viruses D and E are rare in ... Hepatitis. What Is Hepatitis?. Hepatitis (pronounced: hep-uh-TIE-tiss) is an inflammation of the liver. The liver, in the right ... Read more about hepatitis B.. What Is Hepatitis C?. The hepatitis C virus spreads from person to person through blood or other ...
Mystery Hepatitis in Children Still Spreading Across the World, No Cause Identified. ... Spike in Adult Hepatitis Cases Linked to Surge in Homelessness, Opioid Crisis. ... Is SARS-CoV-2 Spike Protein Related to the Hepatitis in Children Outbreak? Heres What We Know. ... Hundreds More Cases of Severe Hepatitis of Unknown Origin Reported in Children. ...
Infectious agents that cause hepatitis include viruses and parasites. Noninfectious causes include certain drugs and toxic ... In some instances hepatitis results from an autoimmune reaction. ... Hepatitis, inflammation of the liver that results from a ... hepatitis C hepatitis B granulomatous hepatitis hepatocellular hepatitis canalicular hepatitis ...(Show more) ... Hepatitis A. Hepatitis A, caused by the hepatitis A virus (HAV), is the most common worldwide. The onset of hepatitis A usually ...
Learn more about the costs of hepatitis C treatment here. ... Hepatitis C is a viral infection with different treatment ... What is hepatitis C viral load?. Hepatitis C viral load refers to how much hepatitis C virus is present in a persons ... Several medications to treat hepatitis C have met FDA approval since then. Costs for hepatitis C treatment remain high, however ... Organizations that offer help to people with hepatitis C, including the American Liver Foundation, Hepatitis Foundation ...
Symptoms of hep E infection are pain in the right side if the abdomen, stool changes, jaundice, and brown or dark urine. Hep E ... The hepatitis E virus is transmitted via the fecal-oral route from eating contaminated foods or drinks. There is no vaccine or ... Hepatitis E is a viral infection caused by the hep E virus. ... cure for hep E infection in the U.S. ... Chronic hepatitis E is more common in most people with hepatitis C. However, hep E occurs less often than hep B, and very ...
... FAQs * WHAT IS HEPATITIS A?. Hepatitis A is a liver disease caused by the hepatitis A virus. It can last a few ... Home » Health » Diseases & Conditions » Information On: » Hepatitis A Hepatitis A. Hepatitis A is a highly contagious liver ... Hepatitis A 2017 Outbreak. LA County Health Alert: Increase in Hep A among Men Who Have Sex with Men (MSM) (November 2, 2017). ... HOW IS HEPATITIS A TREATED?. Hepatitis A goes away on its own in most cases. You can help yourself get better faster by ...
Learn more about the link between hepatitis C and cirrhosis here. ... The liver is a powerful organ that the hepatitis C virus can ... Hepatitis C is a virus that people contract when they come into contact with the blood of someone who has hepatitis C. ... People with hepatitis C may have an increased risk for severe COVID-19 symptoms and liver damage. Learn more about hepatitis C ... Hepatitis C can cause cirrhosis, but cirrhosis cannot cause hepatitis C. This is because a person must have exposure to the ...

No FAQ available that match "hepatitis d"